Why Immunotherapies Have Made DelMar's Lead Drug A Necessity In Brain Cancer
- A large void in the Glioblastoma Multiforme treatment paradigm leaves patients with poor prognosis.
- DelMar is tremendously undervalued on a NPV/DCF basis and relative to peers Northwest Biotherapeutics, Agenus, Celldex, and ImmunoCellular.
- My estimates put fair value at $3.5/share, or 3X upside; analysts have assigned price targets as high as $8/share.
- DelMar's VAL-083 addresses a large GBM population (>50%) unresponsive to standard of care, Temodar, and could be the answer to failures rampant in cancer vaccines (aka immunotherapies).
- VAL-083 has approval in China for the treatment of Lung Cancer and CML. This serves as positive precedence for regulatory approval by the FDA and EMA.